Nasdaq · CIK 0001590877
RGNX REGENXBIO Inc.
Insider trading from SEC Form 4. Last filing 40 d ago. Close $8.07 on Oct 9, 2026, +43% from the 52-week low and -50% from the high.
REGENXBIO Inc. (RGNX) has 50 SEC Form 4 filings on file from 15 insiders, the latest filed on Sep 3, 2026. In the last 90 days insiders made 1 open-market buy worth $949k and 0 open-market sells worth $0, net +$949k.
7 open-market trades have been scored at RGNX. The newest: Gregory Austin Ciongoli (director) bought $949k of stock on Aug 26, 2026, filed Aug 27, 2026, scored 57 (moderate).
RGNX closed at $8.07 on Oct 9, 2026, 43% above its 52-week low and 50% below its 52-week high.
7 Form 144 notices of planned sales are on file, the latest filed Jul 1, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at REGENXBIO Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 57Moderate | Gregory Austin Ciongoli director buy | $949k 102,603 shares | +665% | +66% from low-41% from high | |
| 6Weak | Steve Pakola Chief Medical Officer sell | $169k 15,309 shares | -6% | +35% from low-37% from high | |
| 2Weak | Steve Pakola Chief Medical Officer sell | $53k 5,124 shares | -2% | +86% from low-38% from high | |
| 18Weak | Curran Simpson Chief Executive Officer sell | $263k 20,811 shares | -9% | - | |
| 13Weak | Curran Simpson Chief Executive Officer sell | $76k 7,624 shares | -3% | - | |
| 13Weak | Curran Simpson Chief Executive Officer sell | $77k 7,734 shares | -3% | - | |
| 0Weak | Kenneth T. Mills director sell | $163k 20,602 shares | -4% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 1, 2026 | Stephen J. Pakola Officer | 43,206 0.08% of outstanding | $518k | Jul 1, 2026 | $385k |
| May 11, 2026 | STEPHEN PAKOLA Officer | 34,917 0.07% of outstanding | $368k | May 11, 2026 | $53k |
| Mar 10, 2026 | STEPHEN J PAKOLA Officer | 5,124 0.01% of outstanding | $53k | Mar 10, 2026 | none |
| Oct 9, 2025 | CURRAN M SIMPSON Director, Officer | 20,811 0.04% of outstanding | $254k | Oct 9, 2025 | $154k |
| Sep 10, 2025 | CURRAN M SIMPSON Director, Officer | 15,358 0.03% of outstanding | $152k | Sep 10, 2025 | none |
| May 12, 2025 | KENNETH MILLS Director | 20,602 0.04% of outstanding | $155k | May 12, 2025 | none |
| Dec 30, 2024 | VITTAL VASISTA Officer | 20,041 0.04% of outstanding | $149k | Dec 30, 2024 | none |
Transactions
The newest 50 of 83 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Mitchell Chan Chief Financial Officer | FTax withholding Common Stock | -4,902 | $9.32 | $46k | 122,815 | 40 d ago |
| Sep 1, 2026 | Craig Malzahn Chief Technology Officer | FTax withholding Common Stock | -234 | $9.32 | $2,181 | 81,960 | 40 d ago |
| Aug 25, 2026 | Gregory Austin Ciongoli director | AGrant or award Common Stock | +15,432 | $0.00 | $0 | 15,432 | Aug 27, 2026 |
| Aug 26, 2026 | Gregory Austin Ciongoli director | POpen-market purchase Common Stock | +49,196 | $9.14 | $450k | 64,628 | Aug 27, 2026 |
| Aug 27, 2026 | Gregory Austin Ciongoli director | POpen-market purchase Common Stock | +53,407 | $9.36 | $500k | 118,035 | Aug 27, 2026 |
| Aug 25, 2026 | Gregory Austin Ciongoli director | AGrant or award Stock Options (Right to buy)derivative | +69,609 | $0.00 | $0 | 69,609 | Aug 27, 2026 |
| Aug 1, 2026 | Patrick J. Christmas Chief Strategy & Legal Officer | FTax withholding Common Stock | -4,699 | $9.69 | $46k | 205,968 | Aug 4, 2026 |
| May 29, 2026 | Jean Bennett director | AGrant or award Common Stock | +9,807 | $0.00 | $0 | 28,861 | Jun 2, 2026 |
| May 29, 2026 | Kenneth T. Mills director | AGrant or award Common Stock | +9,807 | $0.00 | $0 | 495,925 | Jun 2, 2026 |
| May 29, 2026 | Allan M. Fox director | AGrant or award Common Stock | +9,807 | $0.00 | $0 | 28,861 | Jun 2, 2026 |
| May 29, 2026 | Daniel Tasse director | AGrant or award Common Stock | +9,807 | $0.00 | $0 | 28,861 | Jun 2, 2026 |
| May 29, 2026 | George Migausky V director | AGrant or award Common Stock | +9,807 | $0.00 | $0 | 28,861 | Jun 2, 2026 |
| May 29, 2026 | David C Stump director | AGrant or award Common Stock | +9,807 | $0.00 | $0 | 28,861 | Jun 2, 2026 |
| May 29, 2026 | Alexandra Glucksmann director | AGrant or award Common Stock | +9,807 | $0.00 | $0 | 28,861 | Jun 2, 2026 |
| May 29, 2026 | Jennifer Zachary director | AGrant or award Common Stock | +9,807 | $0.00 | $0 | 31,871 | Jun 2, 2026 |
| May 29, 2026 | Argeris N Karabelas director | AGrant or award Common Stock | +9,807 | $0.00 | $0 | 28,861 | Jun 2, 2026 |
| May 29, 2026 | George Migausky V director | AGrant or award Stock Options (Right to Buy)derivative | +46,600 | $0.00 | $0 | 46,600 | Jun 2, 2026 |
| May 29, 2026 | Kenneth T. Mills director | AGrant or award Stock Options (Right to Buy)derivative | +46,600 | $0.00 | $0 | 46,600 | Jun 2, 2026 |
| May 29, 2026 | Jean Bennett director | AGrant or award Stock Options (Right to Buy)derivative | +46,600 | $0.00 | $0 | 46,600 | Jun 2, 2026 |
| May 29, 2026 | David C Stump director | AGrant or award Stock Options (Right to Buy)derivative | +46,600 | $0.00 | $0 | 46,600 | Jun 2, 2026 |
| May 29, 2026 | Daniel Tasse director | AGrant or award Stock Options (Right to Buy)derivative | +46,600 | $0.00 | $0 | 46,600 | Jun 2, 2026 |
| May 29, 2026 | Jennifer Zachary director | AGrant or award Stock Options (Right to Buy)derivative | +46,600 | $0.00 | $0 | 46,600 | Jun 2, 2026 |
| May 29, 2026 | Alexandra Glucksmann director | AGrant or award Stock Options (Right to Buy)derivative | +46,600 | $0.00 | $0 | 46,600 | Jun 2, 2026 |
| May 29, 2026 | Argeris N Karabelas director | AGrant or award Stock Options (Right to Buy)derivative | +46,600 | $0.00 | $0 | 46,600 | Jun 2, 2026 |
| May 29, 2026 | Allan M. Fox director | AGrant or award Stock Options (Right to Buy)derivative | +46,600 | $0.00 | $0 | 46,600 | Jun 2, 2026 |
| May 11, 2026 | Steve Pakola Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -15,309 | $11.02 | $169k | 232,617 | May 13, 2026 |
| Mar 10, 2026 | Steve Pakola Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -5,124 | $10.35 | $53k | 247,926 | Mar 12, 2026 |
| Feb 1, 2026 | Patrick J. Christmas Chief Strategy & Legal Officer | FTax withholding Common Stock | -4,700 | $11.16 | $52k | 210,667 | Feb 3, 2026 |
| Feb 1, 2026 | Steve Pakola Chief Medical Officer | FTax withholding Common Stock | -5,267 | $11.16 | $59k | 253,050 | Feb 3, 2026 |
| Jan 27, 2026 | Kenneth T. Mills director | MOption exercise Common Stock | +225,000 | $13.09 | $2.9M | 707,871 | Jan 29, 2026 |
| Jan 27, 2026 | Kenneth T. Mills director | FTax withholding Common Stock | -221,753 | $13.41 | $3.0M | 486,118 | Jan 29, 2026 |
| Jan 27, 2026 | Kenneth T. Mills director | MOption exercise Stock Options (Right to Buy)derivative | -225,000 | $0.00 | $0 | 225,000 | Jan 29, 2026 |
| Jan 6, 2026 | Mitchell Chan Chief Financial Officer | AGrant or award Common Stock | +73,749 | $0.00 | $0 | 127,717 | Jan 8, 2026 |
| Jan 6, 2026 | Patrick J. Christmas Chief Strategy & Legal Officer | AGrant or award Common Stock | +73,749 | $0.00 | $0 | 215,367 | Jan 8, 2026 |
| Jan 6, 2026 | Craig Malzahn Chief Technology Officer | AGrant or award Common Stock | +65,847 | $0.00 | $0 | 82,194 | Jan 8, 2026 |
| Jan 6, 2026 | Steve Pakola Chief Medical Officer | AGrant or award Common Stock | +65,847 | $0.00 | $0 | 258,317 | Jan 8, 2026 |
| Jan 6, 2026 | Curran Simpson Chief Executive Officer | AGrant or award Common Stock | +144,864 | $0.00 | $0 | 342,467 | Jan 8, 2026 |
| Jan 6, 2026 | Mitchell Chan Chief Financial Officer | AGrant or award Stock Options (Right to buy)derivative | +39,650 | $0.00 | $0 | 39,650 | Jan 8, 2026 |
| Jan 6, 2026 | Patrick J. Christmas Chief Strategy & Legal Officer | AGrant or award Stock Options (Right to buy)derivative | +39,650 | $0.00 | $0 | 39,650 | Jan 8, 2026 |
| Jan 6, 2026 | Craig Malzahn Chief Technology Officer | AGrant or award Stock Options (Right to buy)derivative | +35,402 | $0.00 | $0 | 35,402 | Jan 8, 2026 |
| Jan 6, 2026 | Steve Pakola Chief Medical Officer | AGrant or award Stock Options (Right to buy)derivative | +35,402 | $0.00 | $0 | 35,402 | Jan 8, 2026 |
| Jan 6, 2026 | Curran Simpson Chief Executive Officer | AGrant or award Stock Options (Right to buy)derivative | +233,651 | $0.00 | $0 | 233,651 | Jan 8, 2026 |
| Jan 2, 2026 | Patrick J. Christmas Chief Strategy & Legal Officer | FTax withholding Common Stock | -9,793 | $14.40 | $141k | 141,618 | Jan 6, 2026 |
| Jan 2, 2026 | Craig Malzahn Chief Technology Officer | FTax withholding Common Stock | -1,238 | $14.40 | $18k | 16,347 | Jan 6, 2026 |
| Jan 2, 2026 | Steve Pakola Chief Medical Officer | FTax withholding Common Stock | -18,247 | $14.40 | $263k | 192,470 | Jan 6, 2026 |
| Jan 2, 2026 | Curran Simpson Chief Executive Officer | FTax withholding Common Stock | -18,559 | $14.40 | $267k | 197,603 | Jan 6, 2026 |
| Oct 9, 2025 | Curran Simpson Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -20,811 | $12.62 | $263k | 216,162 | Oct 10, 2025 |
| Sep 29, 2025 | Curran Simpson Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -7,624 | $10.03 | $76k | 236,973 | Oct 1, 2025 |
| Sep 10, 2025 | Curran Simpson Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -7,734 | $10.02 | $77k | 244,597 | Sep 12, 2025 |
| Sep 1, 2025 | Mitchell Chan Chief Financial Officer | FTax withholding Common Stock | -4,901 | $8.93 | $44k | 53,968 | Sep 3, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Jean Bennettdirector
- Mitchell ChanChief Financial Officer
- Patrick J. ChristmasChief Strategy & Legal Officer
- Gregory Austin Ciongolidirector, owner, other
- Allan M. Foxdirector
- Alexandra Glucksmanndirector
- Argeris N Karabelasdirector
- George Migausky Vdirector
- Craig MalzahnChief Technology Officer
- Kenneth T. Millsdirector
- Steve PakolaChief Medical Officer
- David C Stumpdirector
- Curran SimpsonChief Executive Officer
- Daniel Tasseceo, officer, director
- Jennifer Zacharyofficer, director
Questions about RGNX
Answered from the filings on this page, as of the latest one.
Are insiders buying RGNX?
As of Sep 3, 2026, SEC Form 4 filings show 1 open-market buy worth $949k by 1 insider and 0 open-market sells worth $0 by 0 insiders at REGENXBIO Inc. in the last 90 days, net +$949k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade RGNX on the open market?
Gregory Austin Ciongoli (director) bought $949k of RGNX on Aug 26, 2026 and filed the Form 4 on Aug 27, 2026. InsiderTell scored 57 (moderate).
How many insiders file Form 4 at REGENXBIO Inc.?
15 people have filed a Form 4 at REGENXBIO Inc., among them Jean Bennett (director), Mitchell Chan (Chief Financial Officer), Patrick J. Christmas (Chief Strategy & Legal Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.